2m 2m 2m 2m 2m 2m 2m
Zhengye-A (ZYBT)
NASDAQ
$0.80-$0.0002 (-0.02%)
Price as of Jun 03, 2026 7:50 PM EDT- N/AMarket Cap
- -87.54%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Zhengye-A (ZYBT)
$0.80-$0.0002 (-0.02%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 116.4M -37.56% | 186.4M N/A | |
Cost of Revenue | 92.5M -2.70% | 95.1M N/A | |
Gross Profit | 23.9M -73.86% | 91.3M N/A | |
Sales and Marketing Expense | 43.9M +6.42% | 41.3M N/A | |
Research and Development Expense | -18.0M +40.79% | -12.8M N/A | |
Depreciation and Amortization Expense | 25.9M +7.12% | 24.2M N/A | |
Total Operating Expenses | 94.4M +26.08% | 74.9M N/A | |
Operating Profit | -70.5M -528.89% | 16.4M N/A | |
Interest Income | 96,000 -58.44% | 231,000 N/A | |
Interest Expense | -3.4M -15.90% | -4.0M N/A | |
Interest Income and Expense and Net | -3.3M -13.33% | -3.8M N/A | |
Total Nonoperating Income and Expense | -1.4M -33.15% | -2.0M N/A | |
Income before Taxes | -71.9M -599.33% | 14.4M N/A | |
Income Taxes | 11.1M +1,100.76% | 924,000 N/A | |
Extraordinary Items | 12.8M +114.71% | 6.0M N/A | |
Net Income | -69.8M -716.96% | 11.3M N/A | |
Net Income from Continuing Operations Applicable to Common | -71.9M -599.33% | 14.4M N/A | |
Basic EPS and Net Income | -1.47 -688.00% | 0.25 N/A | |
Diluted EPS and Net Income | -1.47 -688.00% | 0.25 N/A | |
Basic Weighted Average Shares | 47.3M +3.69% | 45.7M N/A | |
Diluted Weighted Average Shares | 47.3M +3.69% | 45.7M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 50.3M +170.54% | 18.6M N/A | |
Short-Term Investments | 1.6M +8.86% | 1.4M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 51.9M +158.98% | 20.0M N/A | |
Total Current Assets | 137.4M -22.61% | 177.6M N/A | |
Accumulated Depreciation | 131.8M +18.13% | 111.6M N/A | |
Property and Plant and Equipment and Net | 236.8M -7.19% | 255.2M N/A | |
Total Long-Term Assets | 299.1M -5.27% | 315.7M N/A | |
Total Assets | 436.5M -11.51% | 493.2M N/A | |
Income Taxes Payable | 2.4M +18.54% | 2.1M N/A | |
Total Short-Term Debt | 65.8M -19.40% | 81.6M N/A | |
Total Current Liabilities | 120.5M -11.35% | 135.9M N/A | |
Total Long-Term Debt | 8.8M +84.38% | 4.8M N/A | |
Total Long-Term Liabilities | 9.3M +93.35% | 4.8M N/A | |
Total Liabilities | 129.8M -7.78% | 140.7M N/A | |
Retained Earnings | -21.6M -144.93% | 48.2M N/A | |
Total Stockholders Equity | 249.8M -12.01% | 284.0M N/A | |
Total Shares Outstanding | 7.4M -83.81% | 45.7M N/A | |
Cash Flow | |||
Cash from Operating Activities | 13.3M -67.52% | 41.0M N/A | |
Capital Expenditures | 1.0M -92.58% | 13.6M N/A | |
Cash from Investing Activities | -12.6M -54.35% | -27.7M N/A | |
Dividends Paid | N/A N/A | 16.0M N/A | |
Cash from Financing Activities | 32.3M +246.01% | -22.1M N/A | |
Financials Ratio | |||
Gross Margin | 20.51% N/A | N/A N/A | |
Operating Margin | -60.59% N/A | N/A N/A | |
Return on Assets | -15.01% N/A | N/A N/A | |
Return on Equity | -26.15% N/A | N/A N/A | |
Revenue Growth | -37.56% N/A | N/A N/A | |
Current Ratio | 1.14 N/A | N/A N/A | |
Cash Ratio | 0.42 N/A | N/A N/A | |
Debt-to-Equity Ratio | 0.30 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.17 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow